
Siddhartha Ganguly MD FACP
Hematologic Oncology
Associate Director for Clinical Investigation and Research Chief, Division of Hematology. Houston Methodist Hospital and Neal Cancer Center, Houston, TX
Overview of Dr. Ganguly
Dr. Siddhartha Ganguly is a hematologist in Houston, TX and is affiliated with Houston Methodist Hospital. He received his medical degree from Medical College and Hospital Kolkata and has been in practice for over 30 years. He specializes in hematologic oncology and is experienced in bone marrow transplantation, multiple myeloma, lymphoma, and cellular immunotherapy. He has more than 150 publications and over 500 citings. He has been PI for many clinical trials and is the Associate Director for Clinical Investigation at the Houston Methodist Hospital and Neal Cancer Center.
Education & Training
Baylor College of MedicineResidency, Internal Medicine, 1994 - 1995
Southern Illinois UniversityInternship, Internal Medicine, 1993 - 1994
Medical College and Hospital KolkataClass of 1987
Baylor College of MedicineFellowship, Hematology
Certifications & Licensure
OR State Medical License 1999 - Present
KS State Medical License 1995 - 2026
TX State Medical License 2020 - 2026
WA State Medical License 1995 - 2010
IL State Medical License 1993 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma Start of enrollment: 2009 Feb 01
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine Start of enrollment: 2010 Jan 01
- Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma Start of enrollment: 2009 Nov 12
Publications & Presentations
PubMed
- Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.Abu-Sayeef Mirza, Chitra Hosing, Francine Foss, Soyoung Kim, Amy Moskop
Blood Neoplasia. 2026-05-01 - 1 citationsNew comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop
Blood Advances. 2026-01-13 - Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIB...Hemalatha G Rangarajan, Deepakbabu Chellapandian, Rasha Atshan, Kwang Woo Ahn, Sarthak Kumar
Transplantation and Cellular Therapy. 2025-12-28
Journal Articles
- Erythropoietin modulation is associated with improved homing and engraftment post umbilical cord blood transplantationAljitawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantelina A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar..., Blood, 1/19/2016
- Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donorsAbraham S. Kanate, Alberto Mussett, Mohamed A. Kharfan-Dabaja, Kwang W. Ahn, Alyssa DiGilio,Amer Beitinjaneh , Saurabh Chhabra, Timothy S. Fenske, Cesar Freytes, Rober..., Blood, 1/18/2016
- Post-transplant outcomes in high-risk compared to non-high risk multiple myeloma, a CIBMTR analysisScott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kumar S, Kyle R, Lazarus HM, Lee C..., Biol Blood Marrow Transplant, 1/1/2016
Abstracts/Posters
- Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)_Mutated Relapsed/Refractory Acute Myeloid Leukem...Siddhartha Ganguly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)Siddhartha Ganguly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma CellsSiddhartha Ganguly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Disparities in Multiple Myeloma Care in Rural AmericaASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immunotherapy and targeted therapyJoplin, MO - 1/28/2016
Press Mentions
Innovative Allogeneic CAR T Cell Therapy Trial Shows Promising ResultsMarch 27th, 2025- WJMSC‐Derived Small Extracellular Vesicle Enhance T Cell Suppression Through PD‐L1February 8th, 2021
Professional Memberships
- Fellow
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Altius Provider Directory
BCBS Blue Card PPO
BCBS Kansas City Preferred-Care Blue PPO
CIGNA HMO
CIGNA Open AccessCIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









